Search

Your search keyword '"Furst, D. E."' showing total 543 results
Start Over Author "Furst, D. E."
543 results on '"Furst, D. E."'

2. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis

Author

Clegg, D O, Reda, D J, Harris, C L, Klein, M A, O'Dell, J R, Hooper, M M, Bradley, J D, Bingham, C O, Weisman, M H, Jackson, C G, Lane, Nancy E, Cush, J J, Moreland, L W, Schumacher, H R, Oddis, C V, Wolfe, F, Molitor, J A, Yocum, D E, Schnitzer, T J, Furst, D E, Sawitzke, A D, Shi, H, Brandt, K D, Moskowitz, R W, and Williams, H J

Abstract

BACKGROUND: Glucosamine and chondroitin sulfate are used to treat osteoarthritis. The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis. METHODS: We randomly assigned 1583 patients with symptomatic knee osteoarthritis to receive 1500 mg of glucosamine daily, 1200 mg of chondroitin sulfate daily, both glucosamine and chondroitin sulfate, 200 mg of celecoxib daily, or placebo for 24 weeks. Up to 4000 mg of acetaminophen daily was allowed as rescue analgesia. Assignment was stratified according to the severity of knee pain (mild [N=1229] vs. moderate to severe [N=354]). The primary outcome measure was a 20 percent decrease in knee pain from baseline to week 24. RESULTS: The mean age of the patients was 59 years, and 64 percent were women. Overall, glucosamine and chondroitin sulfate were not significantly better than placebo in reducing knee pain by 20 percent. As compared with the rate of response to placebo (60.1 percent), the rate of response to glucosamine was 3.9 percentage points higher (P=0.30), the rate of response to chondroitin sulfate was 5.3 percentage points higher (P=0.17), and the rate of response to combined treatment was 6.5 percentage points higher (P=0.09). The rate of response in the celecoxib control group was 10.0 percentage points higher than that in the placebo control group (P=0.008). For patients with moderate-to-severe pain at baseline, the rate of response was significantly higher with combined therapy than with placebo (79.2 percent vs. 54.3 percent, P=0.002). Adverse events were mild, infrequent, and evenly distributed among the groups. CONCLUSIONS: Glucosamine and chondroitin sulfate alone or in combination did not reduce pain effectively in the overall group of patients with osteoarthritis of the knee. Exploratory analyses suggest that the combination of glucosamine and chondroitin sulfate may be effective in the subgroup of patients with moderate-to-severe knee pain.

Published
2006

3. Proposed Response Parameters for Twelve-Month Drug Trial in Juvenile Systemic Sclerosis: Results of the Hamburg International Consensus Meetings

Author

Foeldvari, I, Torok, K, Anton, J, Blakley, M, Constantin, T, Curran, M, Cutolo, M, Denton, C, Fligelstone, K, Ingegnoli, F, Li, S, Nemcova, D, Orteu, C, Pilkington, C, Smith, V, Stevens, A, Klotsche, J, Khanna, D, Costa-Reis, P, Del Galdo, F, Hinrichs, B, Kasapcopur, O, Pain, C, Ruperto, N, Zheng, A, Furst, D, Foeldvari I., Torok K. S., Anton J., Blakley M., Constantin T., Curran M., Cutolo M., Denton C., Fligelstone K., Ingegnoli F., Li S. C., Nemcova D., Orteu C., Pilkington C., Smith V., Stevens A., Klotsche J., Khanna D., Costa-Reis P., Del Galdo F., Hinrichs B., Kasapcopur O., Pain C., Ruperto N., Zheng A., Furst D. E., Foeldvari, I, Torok, K, Anton, J, Blakley, M, Constantin, T, Curran, M, Cutolo, M, Denton, C, Fligelstone, K, Ingegnoli, F, Li, S, Nemcova, D, Orteu, C, Pilkington, C, Smith, V, Stevens, A, Klotsche, J, Khanna, D, Costa-Reis, P, Del Galdo, F, Hinrichs, B, Kasapcopur, O, Pain, C, Ruperto, N, Zheng, A, Furst, D, Foeldvari I., Torok K. S., Anton J., Blakley M., Constantin T., Curran M., Cutolo M., Denton C., Fligelstone K., Ingegnoli F., Li S. C., Nemcova D., Orteu C., Pilkington C., Smith V., Stevens A., Klotsche J., Khanna D., Costa-Reis P., Del Galdo F., Hinrichs B., Kasapcopur O., Pain C., Ruperto N., Zheng A., and Furst D. E.

Abstract

Objective: Juvenile systemic sclerosis (SSc) is an orphan disease, associated with high morbidity and mortality. New treatment strategies are much needed, but clearly defining appropriate outcomes is necessary if successful therapies are to be developed. Our objective here was to propose such outcomes. Methods: This proposal is the result of 4 face-to-face consensus meetings with a 27-member multidisciplinary team of pediatric rheumatologists, adult rheumatologists, dermatologists, pediatric cardiologists, pulmonologists, gastroenterologists, a statistician, and patients. Throughout the process, we reviewed the existing adult data in this field, the more limited pediatric literature for juvenile SSc outcomes, and data from 2 juvenile SSc patient cohorts to assist in making informed, data-driven decisions. The use of items for each domain as an outcome measure in an open label 12-month clinical trial of juvenile SSc was voted and agreed upon using a nominal group technique. Results: After voting, the domains agreed on were global disease activity, skin, Raynaud's phenomenon, digital ulcers, musculoskeletal, cardiac, pulmonary, renal, and gastrointestinal involvement, and quality of life. Fourteen outcome measures had 100% agreement, 1 item had 91% agreement, and 1 item had 86% agreement. The domains of biomarkers and growth/development were moved to the research agenda. Conclusion: We reached consensus on multiple domains and items that should be assessed in an open label, 12-month clinical juvenile SSc trial as well as a research agenda for future development.

Published
2023

5. Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors: 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

Author

Emery, P, Bingham, C O, III, Burmester, G R, Bykerk, V P, Furst, D E, Mariette, X, van der Heijde, D, van Vollenhoven, R, Arendt, C, Mountian, I, Purcaru, O, Tatla, D, VanLunen, B, and Weinblatt, M E

Published
2017
Full Text
View/download PDF

17. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy

Author

Matucci-Cerinic, M, Allanore, Y, Czirják, L, Tyndall, A, Müller-Ladner, U, Denton, C, Valentini, G, Distler, O, Fligelstone, K, Tyrrel-Kennedy, A, Farge, D, Kowal-Bielecka, O, van den Hoogen, F, Cutolo, M, Sampaio-Barros, P D, Nash, P, Takehara, K, and Furst, D E

Published
2009
Full Text
View/download PDF

19. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR)

Author

Kowal-Bielecka, O, Landewé, R, Avouac, J, Chwiesko, S, Miniati, I, Czirjak, L, Clements, P, Denton, C, Farge, D, Fligelstone, K, Földvari, I, Furst, D E, Müller-Ladner, U, Seibold, J, Silver, R M, Takehara, K, Toth, Garay B, Tyndall, A, Valentini, G, van den Hoogen, F, Wigley, F, Zulian, F, and Matucci-Cerinic, Marco

Published
2009
Full Text
View/download PDF

20. European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research

Author

Avouac, J, Kowal-Bielecka, O, Landewe, R, Chwiesko, S, Miniati, I, Czirjak, L, Clements, P, Denton, C, Farge, D, Fligelstone, K, Földvari, I, Furst, D E, Müller-Ladner, U, Seibold, J, Silver, R M, Takehara, K, Toth, Garay B, Tyndall, A, Valentini, G, van den Hoogen, F, Wigley, F, Zulian, F, and Matucci-Cerinic, M

Published
2009
Full Text
View/download PDF

26. A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout

Author

Taylor, W J, Schumacher, H R, Jr, Baraf, H S B, Chapman, P, Stamp, L, Doherty, M, McQueen, F, Dalbeth, N, Schlesinger, N, Furst, D E, Mellado, J Vazquez, Becker, M A, Kavanaugh, A, Louthrenoo, W, Bardin, T, Khanna, D, Simon, L S, Yamanaka, H, Choi, H K, Zeng, X, Strand, V, Grainger, R, Clegg, D, Singh, J A, Diaz-Torne, C, Boers, M, Gow, P, and Barskova, V G

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results